in addition , no significant differences were observed for any parameters 
 between the groups during the study ( p0.093 ; table 3table 3.hematocrit and biochemistry measurements by day of treatment with pimobendan or 
 benazeprilday01650118202320409506hematocrit ( % ) acei group36 ( 35 , 38)34 ( 32 , 38)34 ( 33 , 38)40 ( 36 , 42)37 ( 35 , 44)38 ( 38 , 40)35 ( 32 , 39)39 ( 36 , 42)pimo group38 ( 36 , 41)35 ( 34 , 38)36 ( 33 , 40)40 ( 38 , 41)37 ( 34 , 38)37 ( 32 , 41)33 ( 33 , 39)37 ( 35 , 40)total protein ( g / dl)acei group7.0 ( 6.5 , 7.2)7.3 ( 6.8 , 7.6)7.0 ( 6.7 , 7.3)6.7 ( 6.5 , 6.9)7.4 ( 7 , 7.4)7.4 ( 7.1 , 7.6)7.0 ( 6.7 , 7.1)7.3 ( 7.1 , 7.5)pimo group6.8 ( 6.7 , 6.8)7.1 ( 6.8 , 7.2)7.3 ( 7.0 , 7.3)6.5 ( 6.4 , 6.7)7.2 ( 7.0 , 7.4)7.1 ( 7.0 , 7.2)6.7 ( 6.5 , 6.8)7.1 ( 6.6 , 7.2)albumin ( g / dl)acei group2.1 ( 2.1 , 2.1)2.2 ( 2.1 , 2.2)2.2 ( 2.1 , 2.2)2.0 ( 1.9 , 2.2)2.2 ( 2.1 , 2.2)2.1 ( 2.0 , 2.1)2.1 ( 2.1 , 2.2)2.3 ( 2.2 , 2.4)pimo group2.1 ( 2.1 , 2.2)2.2 ( 2.2 , 2.3)2.2 ( 2.1 , 2.2)2.1 ( 2.1 , 2.2)2.2 ( 2.2 , 2.3)2.2 ( 2.1 , 2.3)2.2 ( 2.1 , 2.2)2.3 ( 2.3 , 2.4)bun ( mg / dl)acei group20.6 ( 19.4 , 22.8)26.7 ( 26.0 , 27.0)26.8 ( 25.4 , 29.3)24.4 ( 23.4 , 25.3)32.1 ( 28.7 , 32.3)23.8 ( 20.8 , 24.3)23.3 ( 21.4 , 26.5)21.8 ( 21.3 , 25.9)pimo group24.8 ( 22.5 , 25.4)28.3 ( 26.2 , 30.7)26.9 ( 26.6 , 28.5)25.5 ( 23.3 , 28.6)33.7 ( 30.9 , 36.9)26.7 ( 24.6 , 27.9)27.7 ( 24.3 , 30.4)23.9 ( 23.3 , 24.4)creatinine ( mg / dl)acei group0.9 ( 0.8 , 1.0)0.9 ( 0.8 , 1.0)1.0 ( 0.8 , 1.1)0.8 ( 0.7 , 0.8)0.9 ( 0.7 , 0.9)1.1 ( 0.9 , 1.1)1.0 ( 0.8 , 1.0)0.9 ( 0.8 , 0.9)pimo group0.9 ( 0.9 , 1.0)0.9 ( 0.8 , 0.9)0.9 ( 0.8 , 0.9)0.8 ( 0.8 , 0.9)0.8 ( 0.7 , 0.9)0.9 ( 0.9 , 1.0)0.8 ( 0.7 , 1.0)0.8 ( 0.8 , 0.9)sodium ( meq / l)acei group156 ( 156 , 158)155 ( 153 , 155)156 ( 154 , 157)153 ( 152 , 154)154 ( 153 , 155)154 ( 153 , 154)152 ( 151 , 153)148 ( 147 , 150)pimo group158 ( 157 , 159)155 ( 155 , 155)156 ( 155 , 157)153 ( 153 , 154)156 ( 154 , 156)156 ( 153 , 158)154 ( 153 , 154)149 ( 148 , 151)potassium ( meq / l)acei group3.8 ( 3.6 , 4.0)3.9 ( 3.7 , 3.9)3.9 ( 3.7 , 3.9)4.5 ( 4.2 , 5.1)4.0 ( 4.0 , 4.0)4.1 ( 4.0 , 4.3)3.8 ( 3.5 , 3.9)4.3 ( 4.2 , 4.6)pimo group3.7 ( 3.5 , 3.8)3.9 ( 3.7 , 4.3)4.3 ( 4.1 , 4.6)4.3 ( 4.1 , 4.5)3.8 ( 3.7 , 3.8)3.9 ( 3.6 , 4.1)3.7 ( 3.6 , 3.8)4.1 ( 4.0 , 4.3)values are presented as medians ( 25th and 75th percentile ) for hematocrit and 
 biochemistry measurements in both groups before ( day 0 ) and at days 16 , 50 , 118 , 202 , 
 320 , 409 and 506 after drug administration .